Corporate overview
Management
Yves Rosconi, L. Pharm., MBA
President and Chief Executive Officer
Yves Rosconi brings more than 25 years of global pharmaceutical experience to Theratechnologies. He began his career with Abbott Laboratories and went on to spend 21 years with Rhône-Poulenc Rorer in Canada and Australia with increasing responsibilities, ultimately becoming President and General Manager of Canadian operations. After leaving Rhône-Poulenc Rorer, he spent the next two years as Chief Operating Officer of Æterna Laboratories before joining Paris-based Aventis as Senior Vice President, responsible for Africa and the Middle East.
Luc Tanguay, M.Sc., CFA
Senior Executive Vice President and Chief Financial Officer
Luc Tanguay has been active in the biotechnology industry for over 15 years. As a member of senior management at Theratechnologies since 1996, he has contributed to the Company’s growth by facilitating access to public and private capital funding. A member of the Board of Directors since 1993, he has held various management posts since joining the Company. Prior to joining Theratechnologies, Mr. Tanguay had a successful career in investment banking at Lévesque Beaubien (now National Bank Financial) where he helped several organizations establish themselves as public companies.
Marie-Noël Colussi, CA
Vice President, Finance
Marie-Noël Colussi is a graduate of Université du Québec à Montréal in business administration. Prior to joining Theratechnologies, Ms. Colussi worked for eight years with KPMG, a major accounting firm. Ms. Colussi has acquired sound experience in accounting, auditing, control and taxation, particularly in R&D. She joined Theratechnologies in March 1997, and prior to her appointment as Vice President, Finance in February 2002, she successively held the positions of Director, Accounting and Internal Control as well as Controller.
Chantal Desrochers, B. Ph., MBA
Vice President, Business Development and Commercialization
Chantal Desrochers obtained her degree in pharmacy from the Université de Montréal and began her career at Schering-Plough. After obtaining her MBA, Ms. Desrochers joined Bristol-Myers Squibb Company in Canada as Marketing Director Pharmaceuticals and became Vice President, Institutional Business in 1995. In 1997, Ms. Desrochers was promoted as European Franchise Marketing Director, Cardiovascular where she implemented market penetration strategies and contributed to the commercial development of cardiovascular products. This led to her appointment as International Marketing Director, Cardiovascular, at Bristol-Myers Squibb in New Jersey. Prior to joining Theratechnologies, Ms. Desrochers had been offering consulting services in business development and product development strategies.
Andrea Gilpin, Ph.D., MBA
Vice President, Investor Relations & Communications
Responsible for all communications, Dr. Gilpin joined Theratechnologies in 2007. Dr. Gilpin has spent most of her career in the area of Investor Relations in small biotechnologies companies. Dr. Gilpin previously worked at MethylGene, Celmed Biosciences (now Kiadis Pharma), and Nexia Biotechnologies. Over the years, she has also been involved in business development and project/operations management. Dr. Gilpin holds a Ph.D. (genetics/biochemistry) from the University of Toronto and a MBA from the Asper School of Business. She participates on the CIRI Quebec Board of Directors and teaches Investor Relations in the Communications program at McGill University.
Jocelyn Lafond, LL.B., LL.M. 
Vice President, Legal Affairs, and Corporate Secretary
Mr. Lafond has 15 years of experience in the fields of corporate and securities laws. Mr. Lafond holds a law degree from Université Laval and a Masters Degree in Law from the University of Toronto. He has been a member of the Barreau du Québec since 1992. Prior to joining Theratechnologies, Mr. Lafond was a partner with the international law firm of Fasken Martineau DuMoulin, LLP.
Christian Marsolais, Ph. D.
Vice President, Clinical Research and Medical Affairs
Dr. Christian Marsolais has over 15 years of experience in clinical research for large pharmaceutical companies, such as Sandoz Canada and BioChem Therapeutics. Before joining Theratechnologies in 2007, Dr. Marsolais held various positions at Pfizer Global Pharmaceuticals, where he was appointed Director of Medical Affairs, Therapeutic Areas, in 2004. In this position, Dr. Marsolais was responsible of clinical program and scientific initiatives development, as well as the integration of the Scientific Affaires and Clinical Research for the Oncology and HIV Franchise. Dr. Marsolais holds a Ph.D. in biochemistry from the Université de Montréal.
Martine Ortega, Pharm. D.
Vice President, Compliance and Regulatory Affairs
With close to 20 years of experience in the pharmaceutical industry, Martine Ortega has a sound knowledge of the drug development process and has acquired broad expertise in GLP, GCP and cGMP practices and procedures as well as in computerized systems validation. She is also experienced in relations with US and Canadian regulatory agencies. Before joining Theratechnologies in 2006, she held senior management positions at Ventana Clinical Research Corporation in Toronto, as well as MDS Pharma Services and at the Canadian subsidiary of Sandoz in Montréal. Ms. Ortega is a graduate in pharmacy from the Université d’Aix-Marseille II and holds a postdoctoral degree in dermatology.
Pierre Perazzelli, B.Sc.
Vice President, Pharmaceutical Development
A graduate of Université Laval, Pierre Perazzelli has more than 20 years of experience in the pharmaceutical manufacturing industry. Throughout his career, he has held various positions in large pharmaceutical companies, such as Bristol Myers Squibb and Abbott Laboratories. He was Director of the LAB Laboratory, a research centre specializing in pharmaceutical formulation. He is also experienced in the production of generic drugs. Mr. Perazzelli joined Theratechnologies in May 2000.
Krishna Peri, Ph.D.
Vice President, Research
Co-inventor of ExoPep™ technology and a founder of Pharma-G, Dr. Krishna Peri holds a Ph.D. in biochemistry from University of Saskatchewan, Canada. He pursued post-doctoral research in cancer as an NCI fellow at McGill University and at Ste. Justine Hospital Research Center. After the acquisition of Pharma-G by Theratechnologies in 2000, he served as Director of Discovery Research, and was appointed subsequently as Vice-President, Research, in June 2004.